Plain-English translation of NCT06904287 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Migraine research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
Researchers are testing whether adding to prochlorperazine—a medication commonly used to treat severe migraines in the emergency department—works better than the medication alone. This is a randomized trial, meaning you'll be randomly assigned to receive either the standard medication plus , or the standard medication plus a placebo (inactive substance). The goal is to find out if this combination provides faster or better migraine relief.
Many people with severe migraines come to the emergency department looking for relief, but current treatments don't work well enough for everyone. Doctors think that adding might help reduce migraine pain and symptoms more effectively, but this combination hasn't been thoroughly tested yet.
You likely qualify if…
You likely don't qualify if…
You would come to the emergency department with a migraine, and if you qualify and agree to participate, you'll receive an intravenous injection of the first medication. Then you'll be randomly assigned to receive either an intravenous dose of or a placebo saline solution. The research team will monitor how well your migraine improves and track any side effects, with follow-up assessments to compare outcomes between the two groups.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States
Phase
Large-scale testing
Sponsor
Wake Forest University Health Sciences
Enrollment target
~100 participants
Started
December 2025
Primary completion
June 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ryan McKillip, MD
Wake Forest University Health Sciences
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.